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Higher expression levels of activation-induced cytidine deaminase distinguish hairy cell leukemia from hairy cell leukemia-variant and splenic marginal zone lymphoma Leukemia (2010) Hairy cell leukemia (HCL), HCL-variant and splenic marginal zone lymphoma (SMZL) are B-cell disorders that have several pathological features in common, making their distinction at diagnosis sometimes difficult. 1 The normal B-cell counterparts from which these disorders derive are still under debate, and their resemblance suggests that they may share a common clonal progenitor in the splenic marginal zone.
Analysis of the immunoglobulin heavy chain (IGH) locus rearrangements can provide insight into the clonal origin of B-cell disorders. It can determine whether the cell of origin has undergone somatic hypermutation (SHM) and class-switch recombination (CSR) events in response to antigen encounter, and thus can be used to classify disorders based on the B-cell differentiation or activation stage at which they appear to be arrested. SHM and CSR commonly take place in the germinal center (GC), but recent evidence suggests that they can less frequently occur outside of this microenvironment. 2 Expression of activation-induced cytidine deaminase, encoded by the AICDA gene, is required for both SHM and CSR to take place. 3 During normal B-cell development, expression of this enzyme is tightly regulated and is largely confined to GC B cells at the centroblast stage. In line with this, AICDA expression has been detected in subsets of B-cell malignancies with a GC-phenotype such as follicular lymphoma and diffuse large B-cell lymphoma, whereas it is absent in several tumors of pre-and post-GC origin such as precursor B-lymphoblastic leukemia and multiple myeloma, respectively. 4 In chronic lymphocytic leukemia, a disease that can be subdivided into two subgroups based on a SHM threshold of 2%, AICDA expression is found in both subgroups, although more frequently in cases with o2% SHM. 5 We have recently shown that the IGH gene repertoires and SHM patterns of HCL-variant are more similar to that of SMZL than of typical HCL. 6 There has been only one report so far on AICDA mRNA expression in HCL, which found eight of nine cases to express this gene. To date, AICDA expression has not been investigated in HCL-variant or SMZL. To further define the relationships between these three disorders with regard to their clonal evolution, we have quantified the expression of AICDA in a cohort of well-characterized HCL, HCL-variant and SMZL.
On the basis of the availability of high-quality RNA with high tumor-cell purity (median 89%, range 70-98%), 31 cases of HCL, 23 of HCL-variant and 44 of SMZL, acquired before treatment administration, were included in the study. The diagnoses were based on cell morphology, immunophenotyping and bone marrow and/or spleen histology according to the World Health Organization criteria. Five cases of follicular lymphoma and three cases of multiple myeloma were included in the study to act as positive and negative controls of AICDA expression, respectively.
Total RNA was reverse transcribed into cDNA, and AICDA expression was determined by real-time quantitative PCR using the Taqman Gene Expression Assay Hs00757808_m1 (Applied Biosystems, Warrington, UK). As a methodological control gene, we also measured the expression of IL2RA (CD25) (Taqman Gene Expression Assay Hs00907779_m1), an immunophenotypic marker used diagnostically to help distinguish typical HCL from HCL-variant and SMZL. 7 An in-house protocol was used to detect the expression of the endogenous control gene, B2M. All PCR reactions were performed in duplicate on the ABI PRISM 7500 Sequence Detection System (Applied Biosystems) using the recommended protocol for over 40 amplification cycles. To exclude any samples with potentially poor quality RNA, samples with a B2M threshold cycle (C T ) of X23 were removed from the data. Logarithmic expression values for AICDA and IL2RA were calculated using the DC T method. As no DC T values were 422, a DC T value of 22 was imputed for all undetected transcripts and was used as the calibrator value. Dot plots of log AICDA and IL2RA expression levels were generated within Partek Genomics Suite v6.4 (Partek Inc, St Louis, MO, USA).
Detection of cell surface expression of CD25 forms part of an immunophenotypic scoring system performed at diagnosis to help differentiate HCL from HCL-variant and SMZL. Generally, CD25 expression is positive in 495% typical HCL cases, compared with only 10-30% of SMZL and less than 10% of HCL-variant. 8 In line with this, we found expression levels of the gene encoding CD25, IL2RA, to be significantly higher in HCL compared with HCL-variant and SMZL (Mann-Whitney U-test; Po0.0001 for both comparisons, Supplementary Figure 1) , therefore giving confidence in our patient selection and methodological approach.
We have found that AICDA is constitutively expressed in all cases of typical HCL at similar levels to those seen in cases of GC-derived follicular lymphoma (Figure 1 ). This strongly suggests that the HCL cell of origin is arrested at a point during B-cell differentiation when the SHM and/or CSR machinery are still active. Furthermore, in agreement with these results, all cases of HCL show evidence of SHM in their IGHV genes. 6 These results are also in line with the reports of existence of ongoing SHM in HCL cases with mutated IGHV, including those with less than 2% mutations, and also with the production of germline immunoglobulin heavy chain (IgH) transcripts that occur before deletional CSR and coincide with the expression of multiple IgH isotypes in this disorder. 9 Although high AICDA expression in HCL could be interpreted as evidence of a GC origin for this disorder, it has been shown that the HCL gene expression signature most closely resembles that of memory rather than GC B cells. 10 We and others have postulated that transformation of HCL, as well as that of HCL-variant and SMZL, occurs at sites capable of undergoing SHM independent of GC formation. A B-cell population with such abilities has been found to reside within the normal splenic marginal zone. 
Abbreviations: HCL, hairy cell leukemia; SHM, somatic hypermutation; SMZL, splenic marginal zone lymphoma.
a No HCL cases had unmutated IGHV genes.
Letters to the Editor range 3-5) (Mann-Whiney U-test: Po0.0001 for both comparisons, Figure 1 ). Although the difference between HCL-variant and SMZL AICDA expression distributions is marginally significant (Mann-Whitney U-test P ¼ 0.04), this is due to the higher proportion of SMZL cases with undetectable AICDA expression. After the exclusion of cases with undetectable AICDA expression, there is no significant difference between these two groups (P ¼ 0.2). AICDA expression in HCL-variant and SMZL was either low or, similar to cases of post-GC multiple myeloma, completely undetectable. In line with this heterogeneous pattern of AICDA expression, ongoing SHM has been observed in only a proportion of SMZL.
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In contrast to typical HCL, B22% of HCL-variant and 15% of SMZL contain unmutated (0% SHM) IGHV genes. 6 We therefore investigated whether the heterogeneity of AICDA expression in these two disorders was associated with IGHV gene mutation status. Of the cases included in this analysis, IGHV gene mutation data were available for 27 HCL, 22 HCL-variant and 40 SMZL cases. There were no significant differences in AICDA expression levels between the mutated and unmutated subsets of either HCL-variant or SMZL (Table 1a ). This was also true when the cases were divided according to the historically used 2% SHM threshold (Table 1b) . Given the biased use of IGHV4-34 in SMZL and HCL-variant and IGHV1-2 in SMZL, 6 we also investigated whether AICDA expression levels differed between these subgroups compared with the rest of the cases for each disorder. Although we found no significant differences between the subgroups for either disease, this may be due to the low number of cases included in these analyses (IGHV4-34 HCL-variant: 4/22; IGHV4-34 SMZL: 3/40; and IGHV1-2 SMZL: 6/40). The lower level and heterogeneous expression of AICDA in HCL-variant and SMZL might be explained by the presence of tumor sub-clones expressing different levels of AICDA. As we have performed direct sequencing of the whole tumor clone, we cannot rule out the fact that IGHV mutations of small AICDA-expressing sub-populations within the tumor may be present beyond the detection limit of sequencing, and thus accounting for HCL-variant and SMZL cases with truly unmutated IGHV, but displaying low levels of AICDA expression.
We also investigated the potential prognostic impact regarding outcome of the heterogeneous AICDA expression in HCLvariant and SMZL. Overall survival data, as calculated from diagnosis to death and censored at the date of latest follow-up for patients remaining alive, were available for 18/23 HCLvariant and 31/44 SMZL. When HCL-variant and SMZL patient subgroups were defined by logarithmic AICDA expression levels of 0, 1 and 2, no significant associations between AICDA expression and overall survival were identified in either disorder.
Our data suggest that the neoplastic transformation of HCL-variant and SMZL may occur at a similar point in B-cell differentiation, which is different to that of typical HCL. This further strengthens our previous finding that immunogenetically, HCL-variant appears to be similar to SMZL rather than HCL.
